申请人:Daiichi Sankyo Company, Limited
公开号:EP2048150A1
公开(公告)日:2009-04-15
The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I):
wherein
R1 represents a hydrogen atom, an amino group, a hydroxy C1-C6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, etc.; R4 represents a hydrogen atom, a C2-C7 acyl group, etc.; R5, R6, R7, and R8 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, provided that R5, R6, R7 and R8 are not hydrogen atoms at the same time; n is 0 to 4; and X is CH or N.
本发明涉及一种对人类 SGLT1 和/或 SGLT2 活性具有极佳抑制作用的苄基苯基吡喃葡萄糖苷衍生物。本发明提供了由以下通式(I)代表的化合物或其药理学上可接受的盐:
其中
R1 代表氢原子、氨基、羟基 C1-C6 烷基等;R2 代表氢原子等;R3 代表 C1-C6 烷基、羟基 C1-C6 烷基等;R4 代表氢原子、C2-C7酰基等;R5、R6、R7 和 R8 相同或不同,且各自代表氢原子或 C1-C6 烷基,但 R5、R6、R7 和 R8 不能同时为氢原子;n 为 0 至 4;X 为 CH 或 N。